Ads
related to: mds disease- Dosing & Administration
Learn about dosing and
administration now
- Mechanism of Action
Learn about the MOA
of a new treatment option
- Dosing & Administration
Search results
Unhealthy Nails? Kidney Disease Might Be Why—Experts Share Symptoms & Solutions
Fort Worth Star-Telegram· 5 days agoWhen it comes to kidney disease, nails can surprisingly offer critical clues that something is awry. Here’s what you need to know about the link between kidney disease ...
Primary Sjögren Disease Promotes Premature Atherogenesis
Medscape· 4 days agoPatients with primary Sjögren disease with organ involvement were at a high risk for subclinical...
Holistic Health: A Guide to Better Health and Well-Being
Health via Yahoo News· 4 days agoHow To Find a Holistic Health Practitioner Many different providers consider themselves holistic...
Halia Therapeutics to Participate at BIO International Convention and The European Hematology...
The Herald Journal· 6 days agoPreliminary safety, efficacy, and biomarker data from the ongoing Phase II trial evaluating HT-6184 in MDS patients will be presented at the EHA 2024 Hybrid Congress.
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoJasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI...
Benzinga· 4 days agoREDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
Personalized Microbiome-Based Diet Shows Promise for IBS
Medscape· 4 days agoNew research highlighted the potential of a personalized microbiome-based diet, created using the...
Oral Contraceptives May Play a Role in FFA Risk
Medscape· 23 hours agoIn the gene-environment interaction study, a history of OC use was associated with a greater risk for FFA in individuals with a specific CYP1B1 genetic...
Dupilumab: Future Treatment for Pediatric Alopecia Areata?
Medscape· 6 days agoChildren with concomitant atopic dermatitis (AD) and alopecia areata (AA) who were treated with...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 1 day agoFlamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC) PR Newswire LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, June 2, 2024 -Trial-in-Progress poster provides